Enhanced Ω3 Mechanism of Action

Enhanced Ω3 is a patented monoglyceride omega-3 fatty acid researched and developed in Canada. The innovative MaxSimil delivery system was shown to have superior absorption as compared to leading brands of ethyl ester (EE) or reconstituted triglyceride (rTG) fish oils.
The benefits of Omega-3 fatty acids as a food-based therapy are extremely well researched and documented. Clear indications include but are not limited to: cellular anti-oxidation and anti-inflammatory properties. Clinical expertise, documented evidence and patient compliance/value are three key factors crucial in the selection of the appropriate omega-3 fatty acid product.
Most often patient compliance hinges solely on their individual consuming experience. Incomplete digestion of an omega-3 product leading to repeat (fish burp) is a common complaint and a leading factor in poor compliance of fish oil supplementation. Enhanced Ω3 was designed with clinicians and patients in mind; the natural emulsification of Enhanced Ω3 monoglyceride fish oil bypasses the digestive track and facilitates its absorption into the body. Clinically, Enhanced Ω3 demonstrated strong absorption properties even in the absence of any digestive enzymes, a 3X greater absorption rate than standard ethyl ester or reconstituted triglyceride fish oils and allows for increased patient compliance through modest daily serving requirements.
How MaxSimil Works: MaxSimil is a patented delivery system developed by a Canadian professor that allows for the enhanced absorption of lipids into the body. This is achieved by using natural digestive enzymes released by the body; MaxSimil enzymatic process transforms high EPA/DHA fish oils into a monoglyceride emulsion that can be directly absorbed into the intestinal cells bypassing the preliminary stages of digestion.
Bioavailability Study: Enhanced Ω3 coupled with MaxSimil delivery system has been evaluated at great lengths in several Phase I clinical trials. Two human pharmacokinetic studies demonstrated that the advanced absorption system is capable of bypassing digestion for rapid absorption and quickly raises blood plasma concentration of omega-3.
Brunet S., (2020) demonstrated that compared to control ethyl ester, MaxSimil had 3.14 times greater peak plasma concentration in a 24-hour period. Plourde M., (2021) concluded the superior bioavailability of MaxSimil as compared with reconstituted triglyceride (rTG). MaxSimil had 2.1 times greater peak plasma concentration in a 24-hour period. Therefore, 1 gram of MaxSimil fish oil will help reach the same peak plasma concentration versus taking 3 grams of EE fish oil over 24 hours. In the case of rTG, 2 grams of fish oil is needed for every gram of MaxSimil fish oil to reach the same peak blood concentration. The superior bioavailability of MaxSimil predigested monoglyceride means patients have the potential to achieve optimal omega-3 concentration at a lower serving.
Metabolic Benefits: The best evidence for omega-3 supplementation is to help reduce the risk of cardiovascular disease. A 2016 system review assessed the benefit of omega-3 supplementation on triglyceride levels. The analysis used 61 RCTs and 37 longitudinal observational studies to evaluate the current evidence. The REDUCE-IT trial results demonstrated that 4 g of EPA ethyl esters (Icosapent Ethyl) could decrease the risk of major ischemic events, including a 20% reduction in cardiovascular death, in patients with elevated TAG level despite being on statin therapy. Interestingly, early data from a pilot study by Fortin, S., expect 2.0 g of MaxSimil EPA to be equivalent to 4.0 g of Icosapent Ethyl (Vascepa).
Sourcing: Enhanced Ω3 omega fish oils are sourced sustainably from non-GMO and antibiotic-free small fish such as sardines, anchovies and mackerel from cold South American deep waters. Furthermore the fish oil is 3rd party certified including a five-star rating under the International Fish Oil Standards program (IFOS), sustainable fisheries certification by Friend of the Sea (FOS) and the Marine Stewardship Council (MSC) ensuring the highest purity.
Ongoing Research - MaxSimil: Vascepa is a pharmaceutical drug derived from fish oil. This omega-3-like pharmaceutical molecule is used as adjunct treatment alongside statin to reduce the risk of cardiovascular risk in adults with elevated triglycerides. The early data from the clinical trial showed the equivalence of 2 grams of Enhanced Ω3 with MaxSimil to that of 4 grams of Vascepa.
Lactate threshold is a well-known hindrance for many professional athletes striving to achieve peak performance. Inadequate lactate clearance may be a significant and contributing factor in poor physical performance amongst athletes. An on-going pilot study is evaluating if supplementation with MaxSimil omega-3 can effectively decrease the lactic acid concentration. Early data results suggest a reduction of over 26% in lactic acid with the use of omega-3 with MaxSimil at maximum physical exertion. These early and promising results provide additional clinical and therapeutic versatility for Enhanced Ω3 with MaxSimil use in clinical practice.